Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAGNITUDE phase 3 trial of NTLA-2001 in transthyretin amyloidosis with cardiomyopathy
MOH_2024-09-05_013603Phase 3Not yet recruiting
- Sponsor
- Intellia Therapeutics
- Start
- Aug 2024
- Modality
- CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in transthyretin amyloidosis (ATTR) and amyloidotic transthyretin cardiomyopathy (ATTR-CM) comparing NTLA-2001 with Placebo (2 arms). Primary endpoint: Composite cardiovascular endpoint event rate. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
nexiguran ziclumeran
03
Conditions
transthyretin amyloidosis (ATTR)amyloidotic transthyretin cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on MOH_2024-09-05_013603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-09-05_013603.